LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.1 -3.73

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.1

Max

3.26

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-44M

-94M

Pelno marža

-321.09

Darbuotojai

194

EBITDA

-48M

-95M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+209.6% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-07

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

90M

831M

Ankstesnė atidarymo kaina

6.83

Ankstesnė uždarymo kaina

3.1

Naujienos nuotaikos

By Acuity

50%

50%

185 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-16 17:03; UTC

Pagrindinės rinkos jėgos

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025-09-16 16:49; UTC

Pagrindinės rinkos jėgos
Įsigijimai, susijungimai, perėmimai

GD Culture Shares Drop After Deal for Pallas Capital

2025-09-16 16:11; UTC

Pagrindinės rinkos jėgos

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025-09-16 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Strengthens -- Market Talk

2025-09-16 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-09-16 23:20; UTC

Rinkos pokalbiai

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025-09-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025-09-16 20:51; UTC

Rinkos pokalbiai

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 20:25; UTC

Uždarbis

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025-09-16 20:24; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025-09-16 19:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025-09-16 18:52; UTC

Rinkos pokalbiai

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025-09-16 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025-09-16 18:38; UTC

Rinkos pokalbiai

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025-09-16 18:19; UTC

Rinkos pokalbiai

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025-09-16 18:01; UTC

Rinkos pokalbiai

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025-09-16 17:34; UTC

Rinkos pokalbiai

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025-09-16 16:53; UTC

Uždarbis

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025-09-16 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 16:15; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Commodities Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025-09-16 15:22; UTC

Rinkos pokalbiai

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025-09-16 15:21; UTC

Rinkos pokalbiai

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

209.6% į viršų

12 mėnesių prognozė

Vidutinis 10 USD  209.6%

Aukščiausias 12 USD

Žemiausias 5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

185 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat